(Q37703253)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20205617%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

review article

1 reference

title

Recent developments on JAK2 inhibitors: a patent review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20205617%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20205617%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Róbert Kiss

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20205617%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Peter P Sayeski

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20205617%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

language of work or name

English

0 references

publication date

1 April 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20205617%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Patents

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20205617%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20205617%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20205617%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

471-495

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20205617%20AND%20SRC:MED&resulttype=core&format=json

Jaks and STATs: biological implications

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Jak family of kinases in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Kinase drug discovery approaches in chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

JAK2 inhibitors: A reality? A hope?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Novel strategies for patients with chronic myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

The JAK kinases: not just another kinase drug discovery target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Therapeutic targeting of Janus kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Pyridone 6, a pan-Janus-activated kinase inhibitor, suppresses osteoclast formation and bone resorption through down-regulation of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand (RANKL)-induced c-Fos and nuclear factor of activated T

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

An inhibitor of Janus kinase 2 prevents polycythemia in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Fragment-based discovery of JAK-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Jak2 is essential for signaling through a variety of cytokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003639436

Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.1158/1535-7163.MCT-06-0605

Identifiers

DOI

10.1517/13543771003639436

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20205617%20AND%20SRC:MED&resulttype=core&format=json

release_6vscst47jzarppaj7fr2xea6ba

19 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6vscst47jzarppaj7fr2xea6ba

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference